Changes in standard of care (SOC) medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy (HCM): results from the EXPLORER cohort of MAVA-Long-Term Extension (LTE)

Abstract Introduction Mavacamten is efficacious and well tolerated in patients with obstructive HCM in the ongoing MAVA-LTE study (NCT03723655) as shown in previous interim analyses. Here, we present exploratory data from the EXPLORER cohort of MAVA-LTE investigating the effect of changes in SOC tre...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2023-11, Vol.44 (Supplement_2)
Hauptverfasser:	Lakdawala, N, Afshar, K, Barriales-Villa, R, Gimeno-Blanes, J, Michels, M, Saberi, S, Wheeler, M T, Balaratnam, G, Shah, A, Chen, Y M, Sehnert, A J, Abraham, T P
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!